You are browsing articles on the topic of General Archives - CardioExchange

Avatar of Richard Lehman, BM, BCh, MRCGP

Selections from Richard Lehman’s Literature Review: September 1st (1 Sep 2014)

Voices

Richard Lehman, BM, BCh, MRCGP

This week’s topics include aortic valve stenosis, presenting the benefits of PCI to patients, and more.

Avatar of Larry Husten, PHD

Preliminary Outcomes Results For PCSK9 Inhibitor (31 Aug 2014)

News

Amid a slew of new data demonstrating yet again that PCSK9 inhibitors lower LDL cholesterol—drastically and in a wide variety of different patient populations—data from one trial offers the first suggestion that the drugs may in fact improve cardiovascular outcomes. But the analysis, the authors cautioned, is a post-hoc analysis of a trial neither designed nor…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Avatar of Larry Husten, PHD

SIGNIFY Trial Provokes Sound and Fury Over Controversial Drug (31 Aug 2014)

News

The already controversial drug ivabradine just got a little more controversial. The drug, which is marketed by Servier under the brand names of Corlentor and Procoralan, is available in Europe and elsewhere and is used for the treatment of heart failure and stable angina. The drug is not available in the U.S., but it is under development by Amgen for a…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Avatar of CardioExchange Administrator, Staff

ESC.14 Headquarters (30 Aug 2014)

Voices

CardioExchange Administrator, Staff

CardioExchange is dedicated to bringing you the latest from ESC.14. Check out our coverage of the conference here at CardioExchange and don’t forget to tell us what you think! News: PARADIGM-HF Establishes a New Paradigm for Heart Failure Treatment SIGNIFY Trial Provokes Sound and Fury Over Controversial Drug Preliminary Outcomes Results For PCSK9 Inhibitor New Support…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Avatar of Larry Husten, PHD

Predicting PARADIGM-HF, or What to Expect When You’re Expecting (28 Aug 2014)

Voices

Larry Husten, PhD

Larry Husten analyzes the expectations surrounding the upcoming release of PARADIGM-HF and its centerpiece LCZ696 from the perspective of the medical field as well as the world of economics.

Avatar of Larry Husten, PHD

Rise in Popularity of E-Cigarettes Sparks Concerns and Recommendations (25 Aug 2014)

News

The recent dramatic rise in popularity of e-cigarettes threatens to reverse hard-fought progress in the war against smoking, according to a new policy statement from the American Heart Association. “E-cigarettes have caused a major shift in the tobacco-control landscape,” said the lead author of the statement, Aruni Bhatnagar, chair of cardiovascular medicine at the University of Louisville. But…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Avatar of Larry Husten, PHD

FDA Grants Apixaban Expanded Indication for Venous Thromboembolism (21 Aug 2014)

News

The FDA today approved an expanded indication for the oral anticoagulant apixaban (Eliquis, Bristol-Myers Squibb and Pfizer). Apixaban will now be indicated for the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE), and for the reduction in the risk of recurrent DVT and PE (collectively known as venous thromboembolism) after initial therapy. The supplemental new…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Avatar of Harlan M. Krumholz, MD, SM

The Niacin Controversy: What Do You Say to Your Patient? (21 Aug 2014)

Voices

Harlan M. Krumholz, MD, SM

In this scenario based on the HPS2-THRIVE study, Harlan Krumholz asks, “What do you say to your patient?”

Avatar of Larry Husten, PHD

Increased Cardiac Risk Linked to Clarithromycin (19 Aug 2014)

News

Acute use of the popular macrolide antibiotic clarithromycin has been linked to a small but significant increase in cardiac death. In a report in the BMJ, researchers in Denmark analyzed the effects over a 14-year period of the acute use of penicillin V, roxithromycin, and clarithromycin. Earlier research raised concerns that marcrolide antibiotics in general, and erythromycin and azithromycin…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Avatar of Richard Lehman, BM, BCh, MRCGP

Selections from Richard Lehman’s Literature Review: August 18th (18 Aug 2014)

Voices

Richard Lehman, BM, BCh, MRCGP

This week’s topics include the three sodium studies from NEJM, the CLARIFY study, and more.